The Life Sciences team advised Marea Therapeutics on its launch with $190 million in combined Series A and B financings. The Series A round was led by Third Rock Ventures and the Series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and venBio, with the participation of Alpha Wave Global, Omega Funds, Surveyor Capital (a Citadel company) and founding investor Third Rock Ventures. This financing will fund the company’s MAR001 Phase 2 development plan and further progression of additional pipeline programs.
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development to lower remnant cholesterol in adults with metabolic dysfunction and high risk for cardiovascular disease.
The Goodwin team was led by Kimberley Maruncic, Larissa Pinho, Laura Garvey, Leon Levman, Maggie Wong and Kingsley Taft, and included Gozde Guckaya and Jake Osborn (Global Trade), Alexandra Denniston and Chris Jones (Executive Comp/Benefits), Dan Karelitz (Tax) and paralegal Aniko Bouley.
For additional details on the announcement, please read the press release.